Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y.

Oncotarget. 2018 Oct 23;9(83):35394-35407. doi: 10.18632/oncotarget.26247. eCollection 2018 Oct 23.

2.

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.

Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V.

J Immunother Cancer. 2018 Nov 19;6(1):123. doi: 10.1186/s40425-018-0438-3.

3.

Transcriptome-wide identification of transient RNA G-quadruplexes in human cells.

Yang SY, Lejault P, Chevrier S, Boidot R, Robertson AG, Wong JMY, Monchaud D.

Nat Commun. 2018 Nov 9;9(1):4730. doi: 10.1038/s41467-018-07224-8.

4.

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2018 Oct;119(8):950-960. doi: 10.1038/s41416-018-0220-9. Epub 2018 Oct 15.

PMID:
30318514
5.

Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literature.

Delanne J, Nambot S, Chassagne A, Putois O, Pelissier A, Peyron C, Gautier E, Thevenon J, Cretin E, Bruel AL, Goussot V, Ghiringhelli F, Boidot R, Tran Mau-Them F, Philippe C, Vitobello A, Demougeot L, Vernin C, Lapointe AS, Bardou M, Luu M, Binquet C, Lejeune C, Joly L, Juif C, Baurand A, Sawka C, Bertolone G, Duffourd Y, Sanlaville D, Pujol P, Geneviève D, Houdayer F, Thauvin-Robinet C, Faivre L.

Eur J Med Genet. 2018 Aug 28. pii: S1769-7212(18)30122-8. doi: 10.1016/j.ejmg.2018.08.010. [Epub ahead of print] Review.

PMID:
30165243
6.

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.

Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F.

Clin Cancer Res. 2019 Feb 1;25(3):957-966. doi: 10.1158/1078-0432.CCR-18-1940. Epub 2018 Aug 28.

PMID:
30154227
7.

Correction: DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Micheau O, Solary E, Dubrez L.

Cell Death Dis. 2018 Jul 16;9(8):785. doi: 10.1038/s41419-018-0822-4.

8.

Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.

Niogret J, Coudert B, Boidot R.

J Thorac Oncol. 2018 Jul;13(7):e113. doi: 10.1016/j.jtho.2018.02.004. No abstract available.

PMID:
29935845
9.

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Lauret Marie-Joseph E, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L.

Oncoimmunology. 2018 Mar 15;7(6):e1433981. doi: 10.1080/2162402X.2018.1433981. eCollection 2018.

10.

Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases.

Alsadoun N, MacGrogan G, Truntzer C, Lacroix-Triki M, Bedgedjian I, Koeb MH, El Alam E, Medioni D, Parent M, Wuithier P, Robert I, Boidot R, Arnould L.

Mod Pathol. 2018 Sep;31(9):1367-1380. doi: 10.1038/s41379-018-0047-1. Epub 2018 May 21.

PMID:
29785016
11.

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma.

Richard C, Niogret J, Boidot R, Ghiringhelli F.

World J Gastrointest Oncol. 2018 Apr 15;10(4):103-107. doi: 10.4251/wjgo.v10.i4.103.

12.

IRF8-dependent molecular complexes control the Th9 transcriptional program.

Humblin E, Thibaudin M, Chalmin F, Derangère V, Limagne E, Richard C, Flavell RA, Chevrier S, Ladoire S, Berger H, Boidot R, Apetoh L, Végran F, Ghiringhelli F.

Nat Commun. 2017 Dec 12;8(1):2085. doi: 10.1038/s41467-017-01070-w.

13.

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F.

Oncoimmunology. 2017 Jun 16;6(9):e1339856. doi: 10.1080/2162402X.2017.1339856. eCollection 2017.

14.

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model.

Mirjolet C, Boudon J, Loiseau A, Chevrier S, Boidot R, Oudot A, Collin B, Martin E, Joy PA, Millot N, Créhange G.

Int J Nanomedicine. 2017 Aug 30;12:6357-6364. doi: 10.2147/IJN.S139167. eCollection 2017.

15.

Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangère V, Ghiringhelli F.

Oncoimmunology. 2017 Apr 28;6(6):e1321186. doi: 10.1080/2162402X.2017.1321186. eCollection 2017.

16.

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ghiringhelli F.

Anticancer Res. 2017 Jun;37(6):3195-3200.

PMID:
28551664
17.

DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Michaud O, Solary E, Dubrez L.

Cell Death Dis. 2017 May 25;8(5):e2816. doi: 10.1038/cddis.2017.222. Erratum in: Cell Death Dis. 2018 Jul 16;9(8):785.

18.

Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.

Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Végan F, Humblin E, Boidot R, Rébé C, Derangère V, Ladoire S, Apetoh L, Delmas D, Ghiringhelli F.

Cell Rep. 2017 Apr 25;19(4):746-759. doi: 10.1016/j.celrep.2017.04.004.

19.

Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.

Rangan L, Galaine J, Boidot R, Hamieh M, Dosset M, Francoual J, Beziaud L, Pallandre JR, Lauret Marie Joseph E, Asgarova A, Borg C, Al Saati T, Godet Y, Latouche JB, Valmary-Degano S, Adotévi O.

Oncotarget. 2017 Jul 25;8(30):48959-48971. doi: 10.18632/oncotarget.16900.

20.

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

Ghiringhelli F, Richard C, Chevrier S, Végran F, Boidot R.

World J Gastroenterol. 2016 Dec 28;22(48):10680-10686. doi: 10.3748/wjg.v22.i48.10680.

21.

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L.

Oncotarget. 2017 Jan 10;8(2):1957-1971. doi: 10.18632/oncotarget.12699.

22.

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F.

Cancer Res. 2016 Sep 15;76(18):5241-52. doi: 10.1158/0008-5472.CAN-15-3164. Epub 2016 Aug 5.

23.

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.

Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F.

Oncotarget. 2016 Oct 25;7(43):70948-70958. doi: 10.18632/oncotarget.10898.

24.

Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.

Galaine J, Kellermann G, Guillaume Y, Boidot R, Picard E, Loyon R, Queiroz L, Boullerot L, Beziaud L, Jary M, Mansi L, André C, Lethier L, Ségal-Bendirdjian E, Borg C, Godet Y, Adotévi O.

J Immunol. 2016 Sep 1;197(5):1597-608. doi: 10.4049/jimmunol.1502633. Epub 2016 Aug 1.

25.

Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients.

Hennequin A, Derangère V, Boidot R, Apetoh L, Vincent J, Orry D, Fraisse J, Causeret S, Martin F, Arnould L, Beltjens F, Ghiringhelli F, Ladoire S.

Oncoimmunology. 2015 Jun 3;5(2):e1054598. eCollection 2016 Feb.

26.

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.

Kaderbhai CG, Boidot R, Beltjens F, Chevrier S, Arnould L, Favier L, Lagrange A, Coudert B, Ghiringhelli F.

Oncotarget. 2016 Apr 26;7(17):24860-70. doi: 10.18632/oncotarget.8391.

27.

Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions.

Thibaudin M, Chaix M, Boidot R, Végran F, Derangère V, Limagne E, Berger H, Ladoire S, Apetoh L, Ghiringhelli F.

Oncoimmunology. 2015 Jul 6;5(1):e1055444. eCollection 2016.

28.

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F.

Oncotarget. 2016 Feb 23;7(8):9309-21. doi: 10.18632/oncotarget.7008.

29.

A new ER-specific photosensitizer unravels (1)O2-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT.

Pinto A, Mace Y, Drouet F, Bony E, Boidot R, Draoui N, Lobysheva I, Corbet C, Polet F, Martherus R, Deraedt Q, Rodríguez J, Lamy C, Schicke O, Delvaux D, Louis C, Kiss R, Kriegsheim AV, Dessy C, Elias B, Quetin-Leclercq J, Riant O, Feron O.

Oncogene. 2016 Jul 28;35(30):3976-85. doi: 10.1038/onc.2015.474. Epub 2015 Dec 21.

PMID:
26686091
30.

Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing.

Harlé A, Filhine-Tresarrieu P, Husson M, Boidot R, Rouyer M, Dubois C, Leroux A, Merlin JL.

Target Oncol. 2016 Jun;11(3):363-70. doi: 10.1007/s11523-015-0404-7.

PMID:
26661077
31.

Corrigendum: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Bruchard M, Rebé C, Derangère V, Togbé D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Végran F, Ghiringhelli F.

Nat Immunol. 2015 Dec;16(12):1292. doi: 10.1038/ni1215-1292a. No abstract available.

PMID:
26580508
32.

HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.

Boidot R, Chevrier S, Julie V, Ladoire S, Ghiringhelli F.

Int J Colorectal Dis. 2016 Jun;31(6):1245-6. doi: 10.1007/s00384-015-2448-7. Epub 2015 Nov 12. No abstract available.

PMID:
26561417
33.

Transcriptome analysis of TH2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice.

Bruchard M, Boidot R, Ghiringhelli F, Végran F.

Genom Data. 2015 Jul 9;5:314-5. doi: 10.1016/j.gdata.2015.06.031. eCollection 2015 Sep.

34.

Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization.

Courtaut F, Derangère V, Chevriaux A, Ladoire S, Cotte AK, Arnould L, Boidot R, Rialland M, Ghiringhelli F, Rébé C.

Oncotarget. 2015 Sep 29;6(29):26651-62. doi: 10.18632/oncotarget.5791.

35.

The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Bruchard M, Rebé C, Derangère V, Togbé D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Végran F, Ghiringhelli F.

Nat Immunol. 2015 Aug;16(8):859-70. doi: 10.1038/ni.3202. Epub 2015 Jun 22. Erratum in: Nat Immunol. 2015 Dec;16(12):1292.

PMID:
26098997
36.

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.

Schmitt E, Végran F, Chevrier S, Burillier L, Cadouot M, Lizard-Nacol S, Coudert B, Fumoleau P, Arnould L, Boidot R.

BMC Cancer. 2015 Mar 24;15:169. doi: 10.1186/s12885-015-1198-9.

37.

The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy.

Mirjolet C, Boidot R, Saliques S, Ghiringhelli F, Maingon P, Créhange G.

Cancer Treat Rev. 2015 Apr;41(4):354-60. doi: 10.1016/j.ctrv.2015.02.005. Epub 2015 Feb 11. Review.

PMID:
25704912
39.

A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling.

Boidot R, Branders S, Helleputte T, Rubio LI, Dupont P, Feron O.

Oncotarget. 2014 Aug 30;5(16):6947-63.

40.

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.

Chevrier S, Arnould L, Ghiringhelli F, Coudert B, Fumoleau P, Boidot R.

Int J Oncol. 2014 Sep;45(3):1167-74. doi: 10.3892/ijo.2014.2528. Epub 2014 Jun 27.

PMID:
24990411
41.

The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells.

Végran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, Chalmin F, Rébé C, Dérangère V, Ryffel B, Kato M, Prévost-Blondel A, Ghiringhelli F, Apetoh L.

Nat Immunol. 2014 Aug;15(8):758-66. doi: 10.1038/ni.2925. Epub 2014 Jun 29.

PMID:
24973819
42.

Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells.

Végran F, Boidot R.

Oncoimmunology. 2013 Nov 1;2(11):e26328. Epub 2013 Oct 9.

43.

Transcriptional regulation of the survivin gene.

Boidot R, Végran F, Lizard-Nacol S.

Mol Biol Rep. 2014 Jan;41(1):233-40. doi: 10.1007/s11033-013-2856-0. Epub 2013 Nov 7. Review.

PMID:
24197699
44.

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours.

Seront E, Boidot R, Bouzin C, Karroum O, Jordan BF, Gallez B, Machiels JP, Feron O.

Br J Cancer. 2013 Nov 12;109(10):2597-606. doi: 10.1038/bjc.2013.644. Epub 2013 Oct 24.

45.

Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.

Végran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S, Boidot R.

Cancer Res. 2013 Sep 1;73(17):5391-401. doi: 10.1158/0008-5472.CAN-13-0036. Epub 2013 Jul 15.

46.

Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.

Végran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S.

PLoS One. 2013;8(1):e55103. doi: 10.1371/journal.pone.0055103. Epub 2013 Jan 24.

47.

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

Ladoire S, Mignot G, Dalban C, Chevriaux A, Arnould L, Rébé C, Apetoh L, Boidot R, Penault-Llorca F, Fumoleau P, Roché H, Spielmann M, Levy C, Lortholary A, Eichler F, Mesleard C, Bonnetain F, Ghiringhelli F.

Ann Oncol. 2012 Oct;23(10):2552-61. Epub 2012 Mar 19.

PMID:
22431701
48.

A short caspase-3 isoform inhibits chemotherapy-induced apoptosis by blocking apoptosome assembly.

Végran F, Boidot R, Solary E, Lizard-Nacol S.

PLoS One. 2011;6(12):e29058. doi: 10.1371/journal.pone.0029058. Epub 2011 Dec 22.

49.

Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors.

Boidot R, Végran F, Meulle A, Le Breton A, Dessy C, Sonveaux P, Lizard-Nacol S, Feron O.

Cancer Res. 2012 Feb 15;72(4):939-48. doi: 10.1158/0008-5472.CAN-11-2474. Epub 2011 Dec 19.

50.

Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma.

Végran F, Boidot R, Bonnetain F, Cadouot M, Chevrier S, Lizard-Nacol S.

Endocr Relat Cancer. 2011 Dec 1;18(6):783-92. doi: 10.1530/ERC-11-0105. Print 2011 Dec.

PMID:
21878572

Supplemental Content

Loading ...
Support Center